• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ASAIO J . Extracorporeal Membrane Oxygenation Support in COVID-19 Patients: A Propensity Score Analysis

tetano

Editor, Senior Moderator
ASAIO J


. 2022 Nov 14.
doi: 10.1097/MAT.0000000000001829. Online ahead of print.
Extracorporeal Membrane Oxygenation Support in COVID-19 Patients: A Propensity Score Analysis


Alexey Abramov[SUP] 1 [/SUP], Irene Su[SUP] 2 [/SUP], Cara Agerstrand[SUP] 3 [/SUP], Meaghan Flatley[SUP] 1 [/SUP], Richard Dubois[SUP] 1 [/SUP], Danielle Feldhaus[SUP] 4 [/SUP], Bryan P Stanifer[SUP] 5 [/SUP], Joshua Sonett[SUP] 5 [/SUP], Daniel Brodie[SUP] 2 [/SUP], Philippe Lemaitre[SUP] 5 [/SUP]



Affiliations

Abstract

Revised guidelines clarify indications for extracorporeal membrane oxygenation (ECMO) support in Coronavirus disease 2019 (COVID-19) patients with acute respiratory distress syndrome (ARDS). Limited data exist to compare clinical outcomes of COVID-19 ARDS patients to non-COVID-19-related ARDS patients when supported with ECMO. An observational propensity-matched study was performed to compare clinical and ECMO-related complications between COVID-19-related ARDS patients (COVID) and non-COVID-19-related ARDS (Control). COVID- patients cannulated from March 1st, 2020, through June 1st, 2021, were included and matched to patients from the historical cohort at our center from 2012 to 2020 based on age, body mass index (BMI), acute physiology and chronic health evaluation (APACHE) II score, and duration ECMO run. The primary outcome was complications during ECMO therapy. A total of 56 patients were propensity matched 1:1 with a mean age of 40.9 years, BMI 32.1 kg/m2, APACHE II score of 26.6, and duration of ECMO support of 22.6 days. In total 18 COVID-19 patients were observed to have more major bleeding complications (18 vs. 9, p = 0.03). Although not statistically significant, they also had more strokes (6 vs. 3) and required more chest tubes (13 vs. 8). Inpatient mortality was not different. ECMO support in COVID-19 patients is associated with more major bleeding complications, strokes, and chest tube placements. The use of ECMO in patients with COVID-19-related ARDS appears to be associated with an increased risk of complications.
 
Back
Top Bottom